Nesiritide: review of clinical pharmacology and role in heart failure management.
Nesiritide mimics the actions of endogenous B-type natriuretic peptides. Clinical studies on patients who had acute decompensated heart failure demonstrated rapid-onset dose-related vasodilatory effects. Nesiritide reduces pulmonary capillary wedge pressure and improves dypsnea. These effects compared favorably to standard treatments. It decreases preload and afterload and suppresses the renin-angiotensin-aldosterone axis and the release of norepinephrine. Nesiritide also promotes diuresis and has no proarrhythmic effects. Nesiritide is a valuable therapeutic option in the treatment of patients hospitalized for decompensated heart failure. On-going studies target the examination of its long-term effects on mortality and morbidity and its pharmacoeconomic benefits to the healthcare system.
Cheng
Judy W M
JW
Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University and Mount Sinai Medical Center, New York, NY 10029, USA. jcheng@liu.edu
D001682:Biological Availability; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D045283:Natriuretic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D020097:Natriuretic Peptide, Brain; D010601:Pharmacology, Clinical; D018570:Risk Assessment; D012720:Severity of Illness Index; D013329:Structure-Activity Relationship; D016019:Survival Analysis; D016896:Treatment Outcome
D045283:Natriuretic Agents; D020097:Natriuretic Peptide, Brain